VANCOUVER, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc.
(CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise it has
engaged with a dedicated research team at The University of British Columbia (“UBC”) to perform an independent analysis and
validation of the investigative data generated during the course of our clinical study currently underway in California.
Founded in 1915, the University of British Columbia is a global centre for research and teaching, consistently
ranked among the top 20 public universities in the world. With two main campuses, an annual operating budget of $2.5 billion brings
together over 15,000 faculty and staff serving more than 60,000 students.
Lexington’s President Eric Willis notes, “As we move through the various phases of our clinical research
project, the data generated by the San Francisco Bay-area Diablo Clinical Research group will undergo further analysis as a part of
our commitment to scientific validity and regulatory compliance. Accordingly, we are pleased to have enlisted the expertise of the
UBC cardiology research group and look forward to working with them on this project. We are excited about the potential of
establishing a long-term collaboration with UBC and the broader Canadian medical research community. Additionally, we are pleased
to report that our pilot clinical study at Diablo is proceeding according to plan and we are enrolling patients in the second phase
of the pilot study to continue to build statistical support for HeartSentry’s endothelial function diagnosis capabilities.”
The public is invited to follow us on Facebook, Twitter and LinkedIn. To receive our newsletter and news alerts direct to your inbox, you can signup at any
time on any of the signup opportunities or “contact” page of our website.
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which
provides an excellent overview of our business proposition and opportunity ahead
About Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and
monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of the
cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained
technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year
R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued
patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard
of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular
health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the
HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO & Director
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar
expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in such statements.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may
prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of
numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader
is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking
statements contained in this news release are made as of the date of this news release and the Company will update or revise
publicly any of the included forward-looking statements as expressly required by applicable law.
CONTACT:
Lexington Biosciences, Inc.
+1 (800) 320-2640
info@lexingtonbiosciences.com
www.lexingtonbiosciences.com
Renmark Financial Communications Inc.
Laura Welsh: lwelsh@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com
